The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma

Journal of Pediatric Surgery
John B HamnerAndrew M Davidoff

Abstract

Trichostatin A (TSA) is a potent histone deacetylase inhibitor and has demonstrated significant antitumor activity against a variety of cancer cell lines. Type I interferons have also shown significant antitumor as well as antiangiogenic activity. In this study, we examined the effectiveness of combination therapy of TSA and interferon beta (IFN-beta) on human neuroblastoma cells in vitro and in vivo using a murine model of retroperitoneal neuroblastoma. For in vitro experiments, plated human neuroblastoma cells (NB-1643 and NB-1691) were treated with vehicle or with IFN-beta, TSA, or both for 24 hours. Cytotoxicity was assessed by counting cells and expressing the results as a percentage of controls. Expression of the tumor suppressor p21(Waf1) was assessed by Western blot. For in vivo experiments, retroperitoneal neuroblastomas were established in severe combined immune deficiency (SCID) mice. Interferon beta was given using a gene therapy approach, administering 1.5 x 10(10) particles of an adeno-associated virus vector encoding human IFN-beta (AAV hIFN-beta) via tail vein as a single dose per mouse. Trichostatin A was given at a dose of 5 mg/kg every 48 hours subcutaneously. Treatment groups included controls, AAV hIFN-beta...Continue Reading

References

Oct 6, 1998·Annual Review of Biochemistry·G R StarkR D Schreiber
Jun 7, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·S L KominskyB A Torres
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Mar 20, 2002·Cytokine & Growth Factor Reviews·Filippo BelardelliJohn M Kirkwood
Jul 18, 2002·Nature Reviews. Drug Discovery·Ricky W Johnstone
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Guang-Ping GaoJames M Wilson
Jun 2, 2005·Cancer Letters·Christian J StreckAndrew M Davidoff
Jul 30, 2005·Cancer Gene Therapy·C J StreckA M Davidoff
Aug 9, 2005·Experimental Cell Research·Annemieke J M de RuijterAndré B P van Kuilenburg
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian J StreckAndrew M Davidoff
Jun 15, 2006·International Journal of Urology : Official Journal of the Japanese Urological Association·Gong-Cheng LiZhang-Qun Ye
Aug 16, 2006·Journal of Atherosclerosis and Thrombosis·Hiroshi OkamotoMitsuhiro Yokoyama
Jan 19, 2007·International Journal of Cancer. Journal International Du Cancer·Jose A KaramJer-Tsong Hsieh
May 18, 2007·Bioorganic & Medicinal Chemistry Letters·Sandro BelvedereThomas A Miller
Jun 21, 2007·Molecular Cancer Research : MCR·Paxton V DicksonAndrew M Davidoff

❮ Previous
Next ❯

Citations

Nov 6, 2012·BMC Complementary and Alternative Medicine·Rand R HafidhZamberi Sekawi
Jan 16, 2016·Cancers·Laura L Stafman, Elizabeth A Beierle
May 4, 2013·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·M QiJ Ma
Jul 2, 2009·International Journal of Cancer. Journal International Du Cancer·Xudong TangAnh D Le
Jan 3, 2013·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Ana Carolina Uchoa VasconcelosKaren Cherubini
Apr 28, 2018·Experimental & Molecular Medicine·Luz JubierreMiguel F Segura
May 1, 2011·Hormone Molecular Biology and Clinical Investigation·Giorgia UrbinatiJack-Michel Renoir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.